Your session is about to expire
← Back to Search
Pembrolizumab + Bavituximab for Liver Cancer
Study Summary
This trial is testing pembrolizumab and bavituximab to see if they are effective in treating locally advanced HCC.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had major surgery in the last 2 weeks or still have side effects.I have not had any bleeding in my stomach or intestines in the last 2 months.I have active brain tumors causing symptoms.I do not have serious, uncontrolled heart problems.My thyroid condition cannot be controlled with medication.I have an autoimmune disease.I haven't taken steroids or immunosuppressants in the last 14 days.My cancer can be measured on scans and is at least 1 cm big.I have had treatment for liver cancer that spread through my body.My blood pressure is not well controlled.I have both active hepatitis B and C infections.My cancer has spread beyond its original location.I am fully active or can carry out light work.I have noticeable fluid buildup in my abdomen.My liver functions well despite my illness.I am HIV positive.I have a history of lung disease or inflammation not caused by infection.I do not have any severe or uncontrolled health conditions.I am allergic to ingredients in bavituximab, pembrolizumab, or similar drugs.I have been diagnosed with a specific type of liver cancer, but not fibrolamellar, sarcomatoid, or mixed with bile duct cancer.I have had a liver transplant.I am on medication to prevent blood clots.I have previously received immunotherapy targeting PD-1, PD-L1, or PD-L2.I have had a blood clot in the past 6 months.My cancer cannot be treated with surgery or local therapies, or it has spread after such treatments.I had radiotherapy less than 4 weeks ago.I have not had serious infections needing treatment in the last week.I am 18 years old or older.I have an active tuberculosis infection.
- Group 1: Pembro + Bavi
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do you have any openings for enrollees in this clinical trial?
"Correct. According to the information on clinicaltrials.gov, this trial is presently accepting participants since it was first posted in April 2018 and updated most recently in April 2022. To reach their goal of 28 individuals, only one location needs to be staffed with volunteers for enrollment."
To what degree could Pembrolizumab potentially be detrimental to patients?
"With a score of 2, our team at Power has evaluated the safety profile of Pembrolizumab to be adequate due to existing data that indicates it is safe but there being no trial-based evidence for efficacy."
What is the size of the cohort being monitored for this research?
"Affirmative. According to the info on clinicaltrials.gov, this medical study is currently searching for trial participants; it was first posted in April 2018 and last updated in April 2022. 28 people are being sought from a single site."
Have there been previous examinations of Pembrolizumab as a therapeutic approach?
"Currently, there is an abundance of active trials concerning pembrolizumab with 122 reaching the Phase 3 phase. It appears to be most popularly studied in Houston, Texas out of a total of 35,731 locations across the world conducting research on it."
What medical conditions can be effectively treated with Pembrolizumab?
"Pembrolizumab is often prescribed in order to combat malignant neoplasms, as well as non-operable melanomas, microsatellite instability high levels and post-chemotherapy disease progression."
Share this study with friends
Copy Link
Messenger